Victory Capital Management
MLYS icon

Victory Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

Victory Capital Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$914K Buy
33,883
+742
+2% +$20.4K ﹤0.01% 1934
2026
Q1 		$898K Buy
33,141
+260
+0.8% +$7.63K ﹤0.01% 1883
2025
Q4 		$1.19M Buy
32,881
+27,174
+476% +$1.09M ﹤0.01% 1745
2025
Q3 		$216K Buy
+5,707
New +$123K ﹤0.01% 2210

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Victory Capital Management's MLYS Position: Q2 2026 in Review

Victory Capital Management increased its Mineralys Therapeutics (MLYS) stake by 2.2% in Q2 2026, buying an estimated $20.4K and bringing the position to 33,883 shares worth $914K. The position accounts for ﹤0.01% of the portfolio, ranked #1934.

Victory Capital Management first reported a position in MLYS in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.19M in Q4 2025. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Victory Capital Management held 33,883 shares of Mineralys Therapeutics worth $914K as of Q2 2026.
  • Victory Capital Management bought 742 Mineralys Therapeutics shares in Q2 2026, an estimated $20.4K.
  • Mineralys Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1934 holding.
  • Victory Capital Management first reported a position in Mineralys Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Victory Capital Management's Mineralys Therapeutics position peaked at $1.19M in Q4 2025.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.